Literature DB >> 3145820

Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pretreatment.

M D Page1, C Dieguez, R Valcavi, C Edwards, R Hall, M F Scanlon.   

Abstract

In order to investigate the mechanisms by which arginine and L-dopa cause GH release in humans we measured the GH response to GHRH 1-44 (200 micrograms i.v.), arginine (30 g i.v. over 30 min) and L-dopa (500 mg orally) administered alone and 120 minutes following pretreatment with GHRH 1-44 (200 micrograms i.v.) in normal male subjects. Prior GHRH administration abolished the GH response to subsequent GHRH. Arginine infusion induced a rise in GH levels maximal at 45 min. Following GHRH pretreatment the GH response to arginine was enhanced, with peak values of 19.3 +/- 6.4 vs 53.3 +/- 16.5 mU/l (mean +/- SEM) respectively (P less than 0.02). L-dopa alone induced a rise in GH levels maximal at 90 min (17.6 +/- 7.4 mU/l, mean +/- SEM) but this rise was abolished by pretreatment with GHRH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145820     DOI: 10.1111/j.1365-2265.1988.tb03690.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

2.  Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Authors:  J F Garcia-Rojas; A Mangas; A Barba; J Millan; C Dieguez; E Zamora
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

3.  Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

Authors:  M Castagno; A Monzani; S Zanetta; G Genoni; E Giglione; R Ricotti; G Bona; F Prodam; S Bellone
Journal:  J Endocrinol Invest       Date:  2018-02-08       Impact factor: 4.256

4.  Sequential administration of arginine and arginine plus GHRH to test somatotroph function in short children.

Authors:  J Bellone; G Aimaretti; S Bellone; C Baffoni; G Corneli; C Origlia; M Cappa; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

5.  Can a glucagon stimulation test characterized by lower GH cut-off value be used for the diagnosis of growth hormone deficiency in adults?

Authors:  Halit Diri; Zuleyha Karaca; Yasin Simsek; Fatih Tanriverdi; Kursad Unluhizarci; Ahmet Selcuklu; Fahrettin Kelestimur
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

6.  Interaction of L-dopa and GHRH on GH secretion in normal men.

Authors:  J Alba-Roth; C von Creytz; G Mehltretter; J Schopohl; O A Müller; K von Werder
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

7.  Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children.

Authors:  J Bellone; E Bartolotta; G Cardinale; E Arvat; V Cherubini; G Aimaretti; M Maccario; M Mucci; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

8.  A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.

Authors:  E Ghigo; S Goffi; E Arvat; E Imperiale; G M Boffano; M R Valetto; E Mazza; I Santi; A Magliona; M F Boghen
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

Review 9.  Pharmacological therapy for acromegaly: a critical review.

Authors:  Alex F Muller; Aart Jan Van Der Lely
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.

Authors:  E Ghigo; G P Ceda; R Valcavi; S Goffi; M Zini; M Mucci; G Valenti; D Cocchi; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.